Slide 1: An Emerging Leader in Cancer Immuno-Oncology
For personal use only AN EMERGING LEADER IN CANCER IMMUNO-ONCOLOGY Investor Presentation March 2019
Slide 2: Notice: Forward Looking Statements
N O T I C E : F O R W A R D L O O K I N G S TAT E M E N T S For personal use only Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events a
Slide 3: Executive summary
Executive summary For personal use only 1. Innovative immuno-oncology • Imugene is developing a range of novel B cell vaccine therapies to activate the immune system of patients to eradicate tumours approach • Vision to transform and improve the treatment of cancer patients Pages 8-9 2. Addressing a
Slide 4: Key investment highlights
Key investment highlights Strong preliminary results from • Promising Phase 1 clinical trial results across lead candidate B cell vaccines For personal use only ongoing clinical trials • Phase 2 trials open and recruiting patients • Robust pipeline of novel B-cell vaccines targeting large therapeuti
Slide 5: Experienced management team with significant clinical development expertise
Lead by an experienced management team which have significant clinical development commercialisation expertise in the sector Leslie Chong Paul Hopper Dr Axel Hoos Mr Charles Walker For personal use only SYDNEY, AU SYDNEY, AU PHILADELPHIA, USA BRISBANE, AU Managing Director & CEO Executive Chairman N
Slide 6: Scientific Advisory Board
Imugene‘s Scientific Advisory Board consists of world leading oncologist, researchers and developers For personal use only Prof. Josep Tabernero Prof Pravin Kaumaya Dr. Michael Galigiuri VALL D’HEBRON, BARCELONA, Prof Tanios BekaiI Saab OHIO STATE UNIVERSITY, USA CITY OF HOPE, USA SPAIN MAYO CLINIC,
Slide 7: Contents
Contents For personal use only 1 2 3 4 Addressing a Multiple products in Fully funded with several Innovative immuno- significant market clinical stage near term catalysts oncology approach with unmet needs
Slide 8: What problem is Imugene trying to solve with HER-Vaxx?
What problem is Imugene trying to solve with HER-Vaxx? For personal use only HER-2 is a • HER-2 (Human Epidermal clinically and Growth Factor Receptor) HER-2 commercially stimulates cancer cells to grow validated target for cancer treatment • 10 - 30% of gastric, breast, ovarian and pancreatic cance
Slide 9: How does HER-Vaxx work?
How does HER-Vaxx work? 3 Peptides “mimic” the epitope For personal use only (antibody binding site) HER-Vaxx stimulates the patients B cells to produce antibodies that target only those cancer cells with HER-2 on their surface B cells attack the cancer cell TUMOR HER-VAXX B-CELL IMMUNOTHERAPY AC T
Slide 10: Contents
For personal use only 1 2 3 4 Addressing a Multiple products in Fully funded with several Innovative immuno- significant market clinical stage near term catalysts oncology approach with unmet needs
Slide 11: The immuno-oncology market is experiencing robust growth
For personal use only The immuno-oncology market is experiencing robust growth Immuno-oncology is a key treatment Strong sales for leading immuno-oncology treatments Immunotherapy is cutting edge technology The use of immunotherapy is fast becoming a physician preferred treatment over traditional tr
Slide 12: A significant market opportunity across key Imugene vaccines
For personal use only A significant market opportunity across key Imugene vaccines GASTRIC CANCER LUNG CANCER (HER- VAXX) (KEY- VAXX) Newly diagnosed 1m cases per year - globally Incidence 1.8m cases globally, per year cases 19% relate to HER2+ cancers 5 year relative < 25% ~18% survival rate Progno
Slide 13: Cancer immunotherapy attracting big pharma interest
Cancer Immunotherapy is an active market attracting big pharma interest For personal use only Selected partnerships with immunotherapy companies Big-pharma are reaping the rewards of their immunotherapy TARGET CONSIDERATION DATE TECHNOLOGY cancer treatments Oncolytic COMPANY PRODUCT A$500m Jun 2018
Slide 14: Contents
For personal use only 1 2 3 4 Addressing a Multiple products in Fully funded with several Innovative immuno- significant market clinical trials near term catalysts oncology approach with unmet needs
Slide 15: Imugene has a developing pipeline of cancer vaccines
Imugene has a developing pipeline of cancer vaccines Clinical Clinical For personal use only development development Pre-Clinical Phase 1 Phase 2 Key Data / Results • Successful completion of Phase 1b trials • Strong trial results with no safety or toxicity issues HER-Vaxx (HER-2) • All patients had
Slide 16: Harnessing B-cells for cancer immunotherapy
HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY IMUGENE PIPELINE Discovery For personal use only Pipeline Program Pre-clinical ID of candidate Her-1 (EGFR) Her-3 IGF-1R VEGF Combination (numerous) PD-L1 16
Slide 17: HER-Vaxx: Successfully completed Phase 1B study
HER-Vaxx: Successfully completed Phase 1B study… For personal use only Phase 1b – Complete Trial Patients Study Endpoints Study Results • Phase 1b • Gastric Cancer HER-Vaxx in • Recommended Phase • 50 µg selected as the • Open label • Up to 18 patients combination 2 Dose of HER-Vaxx RP2D in 3 cohort
Slide 18: Phase 2 commenced
…and commenced Phase 2 For personal use only Phase 2 commenced - First patient dosed March 2019 Trial Patients Study Primary Endpoints • Phase 2 • Gastric Cancer Randomized • Overall survival • Open label • Up to 70 patients HER-Vaxx in combination • Progression-free • Asia with standard of care sur
Slide 19: KEY-Vaxx: A new entrant in the checkpoint inhibitor market
KEY-Vaxx: A new entrant in the checkpoint inhibitor market For personal use only — KEY-Vaxx is a PD-1 B-cell vaccine, How PD-1 targeted Limitations of current aimed to induce the body to treatments work treatments produce polyclonal antibodies while • Current checkpoint inhibiting existing commercia
Slide 20: PD-1/HER-2 Combination: Potential to increase response rates
PD-1/HER-2 Combination: Potential to increase response rates in HER-2+ cancers For personal use only % CANCER GROWTH INHIBITION IN COLORECTAL CANCER MODEL Immuno-oncology combinations driving value • Combining drugs for better immuno-oncology PD-1 vaccine plus Her-2 vaccine 90% outcome is driving va
Slide 21: KEY-Vaxx: Vaccine in Phase development path
KEY-Vaxx: Vaccine in Phase 1 development path Current status For personal use only PRE-CLINICAL MILSTONES PD-1 Formal Finalise 2019: candidate CMC pre-clinical FDA/IND regulatory IND Commence vaccine manufacturing Pre-clinical FDA de- granted submissions Phase 1 identified briefing meeting Phase 1 –
Slide 22: Contents
For personal use only 1 2 3 4 Addressing a Multiple products in Fully funded with several Innovative immuno- significant market clinical stage near term catalysts oncology approach with unmet needs
Slide 23: Robust cash position with supportive institutional shareholder base
For personal use only Robust cash position with supportive institutional shareholder base Public Market Overview Share Price Performance (last 6 months) Share Price 1 A$0.02 Price (A$) Volume (k) 0.030 160,000 Market Capitalisation 2 A$72.2M IMU releases IMU advances to appendix 4C results phase II
Slide 24: Clinical development and milestones
Clinical development and milestones Phase 2 clinical trials for key indications underway – trials underpinned by For personal use only additional value-adding studies and an exciting pipeline With a proactive approach to business development and brand awareness through participation in key STUDIES 1
Slide 25: Leslie Chong, Managing Director & CEO
For personal use only Leslie Chong Managing Director & CEO leslie.chong@imugene.com +61 458 040 433